Advertisement

Annals of Surgical Oncology

, Volume 10, Issue 3, pp 297–304 | Cite as

Quantitative Analysis of Heparanase Gene Expression in Esophageal Squamous Cell Carcinoma

  • Masahide Ikeguchi
  • Kenji Fukuda
  • Ken-ichi Yamaguchi
  • Akira Kondo
  • Shun-ichi Tsujitani
  • Nobuaki Kaibara
Original Articles

Abstract

Background: Heparan sulfate proteoglycans, the main components of the extracellular matrix, are recognized as important components of signal transduction and play an important role in tumor progression. Heparanase (hep) degrades heparan sulfate proteoglycans, but the clinical importance of hep is unclear. In this study, we investigated the clinicopathologic importance of hep messenger RNA (mRNA) expression in esophageal squamous cell carcinoma (ESCC).

Methods: Fresh tumors and noncancerous epithelia were obtained from 57 ESCC patients after esophagectomy. Expression levels of hep and glyceraldehyde-3-phosphate dehydrogenase mRNA were quantitatively analyzed by real-time reverse transcriptase-polymerase chain reaction. Apoptotic cancer cells and microvessel density were evaluated immunohistochemically.

Results: The relative hep mRNA expression level (hep:glyceraldehyde-3-phosphate dehydrogenase ratio) in ESCC was lower than in noncancerous tissue (P < .001). Tumor hep expression decreased according to tumor progression and correlated with the occurrence of apoptotic cancer cells, but not with tumor microvessel density. Moreover, low hep expression correlated with poor patient survival.

Conclusions: Reduced hep mRNA expression might result in abnormal cell growth and correlate with ESCC progression.

Key Words

Apoptosis Esophageal squamous cell carcinoma Heparan sulfate proteoglycans Heparanase Real-time reverse transcriptase-polymerase chain reaction 

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

REFERENCES

  1. 1.
    Hosch SB, Stoecklein NH, Pichlmeier U, et al. Esophageal cancer: the mode of lymphatic tumor cell spread and its prognostic significance. J Clin Oncol 2001; 19: 1970–5.Google Scholar
  2. 2.
    Liotta LA, Steeg PS, Stetler-Stevenson WG. Cancer metastasis and angiogenesis: an imbalance of positive and negative regulation. Cell 1991; 64: 327–36.CrossRefPubMedGoogle Scholar
  3. 3.
    Hulett MD, Hornby JR, Ohms SJ, et al. Identification of active-site residues of the pro-metastatic endoglycosidase heparanase. Biochemistry 2000; 39: 15659–67.Google Scholar
  4. 4.
    Vlodavsky I, Friedmann Y, Elkin M, et al. Mammalian heparanase: gene cloning, expression and function in tumor progression and metastasis. Nat Med 1999; 5: 793–802.Google Scholar
  5. 5.
    Hulett MD, Freeman C, Hamdorf BJ, Baker RT, Harris MJ, Parish CR. Cloning of mammalian heparanase, an important enzyme in tumor invasion and metastasis. Nat Med 1999; 5: 803–9.Google Scholar
  6. 6.
    Gohji K, Hirano H, Okamura M, et al. Expression of three extracellular matrix degradative enzymes in bladder cancer. Int J Cancer 2001; 95: 295–301.Google Scholar
  7. 7.
    Endo K, Maehara Y, Baba H, et al. Heparanase gene expression and metastatic potential in human gastric cancer. Anticancer Res 2001; 21: 3365–70.Google Scholar
  8. 8.
    Yayon A, Klagsbrun M, Esko JD, Leder P, Ornitz DM. Cell surface, heparin-like molecules are required for binding of basic fibroblast growth factor to its high affinity receptor. Cell 2001; 64: 841–8.Google Scholar
  9. 9.
    Nugent MA, Iozzo RV. Fibroblast growth factor-2. Int J Biochem Cell Biol 2000; 32: 115–20.Google Scholar
  10. 10.
    Rapraeger AC, Krufka A, Olwin BB. Requirement of heparan sulfate for bFGF-mediated fibroblast growth and myoblast differentiation. Science 1991; 252: 1705–8.Google Scholar
  11. 11.
    Mundhenke C, Meyer K, Drew S, Friedl A. Heparan sulfate proteoglycans as regulators of fibroblast growth factor-2 receptor binding in breast carcinomas. Am J Pathol 2002; 160: 185–94.Google Scholar
  12. 12.
    Koliopanos A, Friess H, Kleeff J, et al. Heparanase expression in primary and metastatic pancreatic cancer. Cancer Res 2001; 61: 4655–9.PubMedGoogle Scholar
  13. 13.
    Cheung IY, Cheung NV. Quantitation of marrow disease in neuroblastoma by real-time reverse transcription-PCR. Clin Cancer Res 2001; 7: 1698–705.Google Scholar
  14. 14.
    Yajima T, Yagihashi A, Kameshima H, et al. Quantitative reverse transcription-PCR assay of the RNA component of human telomerase using the TaqMan fluorogenic detection system. Clin Chem 1998; 44: 2441–5.Google Scholar
  15. 15.
    Mitas M, Mikhitarian K, Walters C, et al. Quantitative real-time RT-PCR detection of breast cancer micrometastasis using a multigene marker panel. Int J Cancer 2001; 93: 162–71.Google Scholar
  16. 16.
    Ikeguchi M, Sakatani S, Ueta T, et al. The expression of thymidine phosphorylase suppresses spontaneous apoptosis of cancer cells in esophageal squamous cell carcinoma. Pathobiology 2001; 69: 36–43.Google Scholar
  17. 17.
    Nakajima M, Irimura T, Di Ferrante N, Nicolson GL. Metastatic melanoma cell heparanase. Characterization of heparan sulfate degradation fragments produced by B16 melanoma endoglucuronidase. J Biol Chem 1982; 259: 2283–90.Google Scholar
  18. 18.
    Ikuta M, Podyma KA, Maruyama K, Enomoto S, Yanagishita M. Expression of heparanase in oral cancer cell lines and oral cancer tissues. Oral Oncol 2001; 37: 177–84.Google Scholar
  19. 19.
    Ogawa K, Nakanishi H, Takeshita F, et al. Establishment of rat hepatocellular carcinoma cell lines with differing metastatic potential in nude mice. Int J Cancer 2001; 91: 797–802.Google Scholar
  20. 20.
    Kuniyasu H, Oue N, Tsutsumi M, Tahara E, Yasui W. Heparan sulfate enhances invasion by human colon carcinoma cell lines through expression of CD44 variant exon 3. Clin Cancer Res 2001; 7: 4067–72.PubMedGoogle Scholar
  21. 21.
    Liu D, Shriver Z, Venkataraman G, Shabrawi YE, Sasisekharan R. Tumor cell surface heparan sulfate as cryptic promoters or inhibitors of tumor growth and metastasis. Proc Natl Acad Sci U S A 2002; 99: 568–73.Google Scholar
  22. 22.
    Elkin M, Ilan N, Ishai-Michaeli R, et al. Heparanase as mediator of angiogenesis: mode of action. FASEB J 2001; 15: 1661–3.Google Scholar
  23. 23.
    El-Assal ON, Yamanoi A, Ono T, Kohno H, Nagasue N. The clinicopathological significance of heparanase and basic fibroblast growth factor expression in hepatocellular carcinoma. Clin Cancer Res 2001; 7: 1299–305.Google Scholar
  24. 24.
    Ginath S, Menczer J, Friedmann Y, et al. Expression of heparanase, Mdm2, and erbB2 in ovarian cancer. Int J Oncol 2001; 18: 1133–44.Google Scholar
  25. 25.
    Suzuki R, Takemura K, Tsutsumi M, Nakamura S, Hamajima N, Seto M. Detection of cyclin D1 overexpression by real-time reverse-transcriptase-method quantitative polymerase chain reaction for the diagnosis of mantle cell lymphoma. Am J Pathol 2001; 159: 425–9.Google Scholar

Copyright information

© The Society of Surgical Oncology, Inc. 2003

Authors and Affiliations

  • Masahide Ikeguchi
    • 1
    • 3
  • Kenji Fukuda
    • 2
  • Ken-ichi Yamaguchi
    • 2
  • Akira Kondo
    • 2
  • Shun-ichi Tsujitani
    • 2
  • Nobuaki Kaibara
    • 2
  1. 1.Division of Operating RoomFaculty of Medicine, Tottori UniversityYonagoJapan
  2. 2.Division of Surgical OncologyFaculty of Medicine, Tottori UniversityYonagoJapan
  3. 3.Division of Operating RoomFaculty of Medicine, Tottori UniversityJapan

Personalised recommendations